Previous work has determined that ZEB2 is a key genetic determinant in AML initiation/progression and that Zeb2 knockdown (KD) in retroviral MLL-AF9 models of AML decreases cellular proliferation and enhances myeloid differentiation in vitro [16]. Here, KMT2A is linked to acute myeloid leukemia.